Bausch + Lomb Corporation Common Shares (NY:BLCO)

16.18 +0.37 (+2.34%)

Delayed Quote Updated: 10:17 AM EDT, Oct 14, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Bausch + Lomb Corporation Common Shares

< Previous 1 2 3 4 5 6 7 8 9

...

12 13 Next >

3 Reasons BLCO is Risky and 1 Stock to Buy Instead

March 26, 2026

Even during a down period for the markets, Bausch + Lomb has gone against the grain, climbing to $16.01. Its shares have yielded a 10.4% return over the last...

Via StockStory

Topics Bankruptcy

A Bausch + Lomb Director Just Bought $77,000 in Stock. That's Only Half the Story ↗

March 24, 2026

Bausch + Lomb, a global leader in eye health products and surgical devices, reported a recent insider buy amid ongoing sector activity.

Via The Motley Fool

Topics Regulatory Compliance

Bausch + Lomb Announces Positive 24-Month U.S. Data on the ELIOS™ System for Treatment of Glaucoma

March 23, 2026

From Bausch + Lomb Corporation

Via Business Wire

Billboard Giant Posts $1.6 Billion Revenue as $20.5 Million Bet Makes It a Top Portfolio Holding ↗

March 12, 2026

This outdoor advertising firm operates a vast network of displays across the Americas and Europe, serving a diverse global client base.

Via The Motley Fool

Topics Regulatory Compliance

Bausch + Lomb Corp (NYSE:BLCO) Reports Mixed Q4 2025 Results: Revenue Beat, EPS Miss ↗

February 18, 2026

Via Chartmill

Eye Care Giant Posts $5.1 Billion in Revenue as One Investor Builds Major Position ↗

March 12, 2026

Bausch + Lomb provides eye health products and surgical devices globally, serving both healthcare professionals and consumers.

Via The Motley Fool

Topics Regulatory Compliance

Bausch + Lomb Launches R&D “Teach-in” Webinar Series

March 09, 2026

From Bausch + Lomb Corporation

Via Business Wire

Integra LifeSciences, GE HealthCare, Bausch + Lomb, ICU Medical, and Universal Health Services Shares Are Falling, What You Need To Know

March 06, 2026

Via StockStory

Topics Earnings Economy

2 Profitable Stocks Worth Investigating and 1 We Ignore

March 04, 2026

Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today does...

Via StockStory

Viatris (VTRS): From Debt-Laden Merger to Specialty Powerhouse—A 2026 Research Deep Dive

March 03, 2026

As of March 3, 2026, Viatris Inc. (NASDAQ: VTRS) stands at a pivotal crossroads in its corporate evolution. Formed less than six years ago through one of the most complex healthcare mergers in recent...

Via Finterra

Topics Economy Initial Public Offering Retirement

5 Revealing Analyst Questions From Bausch + Lomb’s Q4 Earnings Call

February 25, 2026

Bausch + Lomb’s fourth quarter showed strong revenue growth but fell short on non-GAAP profit expectations, prompting a modestly negative market reaction. Management attributed the performance to...

Via StockStory

Topics Earnings

Ophthalmology and Therapy Publishes Findings Showing Lifestyle-Driven Rise in Ocular Redness and Differentiated Role of LUMIFY®

February 24, 2026

From Bausch + Lomb Corporation

Via Business Wire

3 Small-Cap Stocks We Steer Clear Of

February 22, 2026

Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that these businesses have increased downside...

Via StockStory

BLCO Q4 2025 Deep Dive: Dry Eye and Product Innovation Propel Growth, Margin Expansion in Focus

February 19, 2026

Eyecare company Bausch + Lomb (NYSE:BLCO) announced better-than-expected revenue in Q4 CY2025, with sales up 9.8% year on year to $1.41 billion. The company’s full-year revenue guidance of $5.43...

Via StockStory

Bausch + Lomb’s (NYSE:BLCO) Q4 CY2025: Beats On Revenue

February 18, 2026

Eyecare company Bausch + Lomb (NYSE:BLCO) announced better-than-expected revenue in Q4 CY2025, with sales up 9.8% year on year to $1.41 billion. The company’s full-year revenue guidance of $5.43...

Via StockStory

Bausch + Lomb Announces Fourth-Quarter and Full-Year 2025 Results, Provides 2026 Guidance

February 18, 2026

From Bausch + Lomb Corporation

Via Business Wire

Bausch + Lomb (BLCO) Q4 Earnings: What To Expect

February 16, 2026

Eyecare company Bausch + Lomb (NYSE:BLCO) will be reporting results this Wednesday before market hours. Here’s what to look for.

Via StockStory

Topics World Trade

3 Reasons to Sell BLCO and 1 Stock to Buy Instead

February 09, 2026

Bausch + Lomb’s 24.2% return over the past six months has outpaced the S&P 500 by 15.6%, and its stock price has climbed to $16.93 per share. This was partly thanks to its solid quarterly results, and...

Via StockStory

Topics Bankruptcy Stocks

1 Healthcare Stock to Research Further and 2 Facing Headwinds

January 29, 2026

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Shareholders who bet on the industry have been rewarded lately as healthcare...

Via StockStory

Topics Stocks

3 Stocks Under $50 That Fall Short

January 26, 2026

Stocks trading between $10 and $50 can be particularly interesting as they frequently represent businesses that have survived their early challenges. However, investors should remain vigilant as some...

Via StockStory

3 Cash-Burning Stocks We’re Skeptical Of

January 22, 2026

Companies that burn cash at a rapid pace can run into serious trouble if they fail to secure funding. Without a clear path to profitability, these businesses risk dilution, mounting debt, or even...

Via StockStory

Topics Bankruptcy

Bausch + Lomb Will Release Fourth-Quarter and Full-Year 2025 Financial Results on Feb. 18

January 20, 2026

From Bausch + Lomb Corporation

Via Business Wire

Bausch + Lomb Partners with Glaucoma Research Foundation and The Glaucoma Foundation to Address a Leading Cause of Irreversible Blindness in the U.S.

January 05, 2026

From Bausch + Lomb Corporation

Via Business Wire

Bausch + Lomb Completes Refinancing of Outstanding Term B Loans

January 02, 2026

From Bausch + Lomb Corporation

Via Business Wire

Bausch + Lomb to Participate in the 44th Annual J.P. Morgan Healthcare Conference

December 23, 2025

From Bausch + Lomb Corporation

Via Business Wire

1 Profitable Stock to Keep an Eye On and 2 We Question

December 17, 2025

While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, "Your margin is my...

Via StockStory

Fund Exits $6.6 Million Bausch + Lomb Stake as Shares Lag by 9% This Past Year ↗

December 17, 2025

Strong operating results did not stop one fund from walking away entirely, raising questions about how much patience volatile healthcare names really command.

Via The Motley Fool

Bausch + Lomb Announces Two Board of Directors Appointments

December 17, 2025

From Bausch + Lomb Corporation

Via Business Wire

Bausch + Lomb Announces Refinancing of Outstanding Term B Loans

December 12, 2025

From Bausch + Lomb Corporation

Via Business Wire

Why Bausch + Lomb (BLCO) Stock Is Trading Up Today

December 11, 2025

Shares of eyecare company Bausch + Lomb (NYSE:BLCO) jumped 2.2% in the morning session after Citigroup upgraded its rating on the company's shares to Buy from Neutral and raised its price target. The...

Via StockStory

Topics Artificial Intelligence Initial Public Offering

< Previous 1 2 3 4 5 6 7 8 9

...

12 13 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.